KISUNLA
Jul 24, 2026
Aβ-Protein Inhibitors in Alzheimer’s Disease: The Amyloid-Busting Arsenal Redefining Care
Summary Alzheimer’s disease treatment has shifted from symptomatic management to disease modification with the emergence of anti-amyloid beta (Aβ) inhibitors that target the root cause by clearing amyloid plaques. Biogen/Eisai’s LEQEMBI and Eli Lilly’s KISUNLA are currently the only Aβ-targeting therapies to...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
